We are pleased to let you know that Elsevier, the publisher of *Vaccine*, has developed a new Access Program, which will provide free access to all of the content in selected Elsevier journals in the fields of vaccine research and virology. The program, which includes this journal, will run until the end of October.

As of this week, the full content (html and PDFs) of *Vaccine* will be made freely available on ScienceDirect through the [Elsevier Coronavirus Researcher Hub.]{.ul} This hub offers free access to a broad collection of resources and solutions for scientists whose work focuses on basic and clinical vaccine research, vaccine manufacturing, vaccine safety, and other vaccine-related research. Eligible researchers can apply for access at the  [Hub.]{.ul}  So far, more than 630 researchers have been granted access to the content of the Hub, and the site has received nearly 20,000 unique visitors.

Please note that the free access to the full content of these journals is in addition to the  [ScienceDirect COVID-19 collection]{.ul}, which is currently offering free access to more than 30,000 Covid-19 related articles.

We are pleased to participate in this program and offer you, our readers and authors, this benefit. Please let us know how this benefitted you and share any comments you may have for improvement.

There is much science to do, and together we can advance the science in this difficult global pandemic.
